"In an industry where demand is stronger than ever and expectations had increased into the print, a $50mn raise to ‘24 EBITDA guidance was not enough," one analyst wrote.
Howmet Aerospace reported strong Q1 FY24 results, with revenue up 14% and adjusted EPS beating expectations. Outlook has been raised, but 737 MAX production remains a concern.
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX shares Outperform.
Enovix said quarterly sales came in at $5.272 million, beating the analyst consensus estimate of $3.779 million by 39.53% and representing a large increase over sales of $21,000 from the same period last year. The company also announced a development agreement with one of the top five smartphone OEMs in the world by unit volume.